Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 75 versus FENTANYL CITRATE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 75 versus FENTANYL CITRATE PRESERVATIVE FREE.
FENTANYL-75 vs FENTANYL CITRATE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system, leading to decreased neurotransmitter release and hyperpolarization of neurons.
Synthetic opioid agonist; primarily binds to mu-opioid receptors in the CNS, modulating nociceptive pathways and producing analgesia, sedation, and euphoria.
Apply 75 mcg/h transdermally every 72 hours for opioid-tolerant patients; not for acute pain. Rotate application site.
Initial: 50-100 mcg IV every 2-5 minutes as needed for pain. For anesthesia: 2-50 mcg/kg IV bolus, then 0.7-10 mcg/kg/hr infusion.
None Documented
None Documented
Terminal elimination half-life: 3-12 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, or continuous infusion.
Terminal elimination half-life is approximately 2–4 hours in healthy adults, but may be prolonged to 4–12 hours in elderly, critically ill, or obese patients due to increased volume of distribution and decreased clearance. Context: Duration of action after a single bolus is relatively short due to redistribution, but accumulation can occur with repeated doses or infusions, leading to prolonged effects.
Renal: ~75% as metabolites (primarily norfentanyl) and ~10% unchanged; fecal: ~9%; biliary: minor.
Primarily hepatic metabolism via CYP3A4, with approximately 75% of the dose excreted in urine as metabolites (primarily norfentanyl) and <10% as unchanged fentanyl. About 9% is excreted in feces. Minimal biliary excretion.
Category D/X
Category D/X
Opioid Agonist
Opioid Agonist